Haematologic malignancies
Clinical research at Universitaetsklinikum Ulm AöR includes Waldenström’s macroglobulinemia, marginal zone lymphoma, and acute myeloid leukemia, with attention to both newly diagnosed and relapsed disease.
- Waldenström’s macroglobulinemia
- Marginal zone lymphoma
- Acute myeloid leukemia
The portfolio reflects interest in B-cell lymphoproliferative disorders and myeloid neoplasms, including genetically defined AML subgroups.
Breast cancer
The sponsor is active in HER2-positive and HER2-low early breast cancer as well as hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.
- HER2-positive early breast cancer
- HER2-low early breast cancer
- Hormone receptor-positive HER2-negative advanced breast cancer
Research interest extends to molecular relapse and treatment strategies for advanced disease.
Pancreatic cancer
Trials also address pancreatic ductal adenocarcinoma in the setting of functionally resectable disease after surgery.
- Pancreatic ductal adenocarcinoma
- Adjuvant treatment selection
- Post-operative disease monitoring
This area includes interest in tumour profiling and personalised treatment selection for resected pancreatic cancer.
Precision oncology and response assessment
Across its studies, the sponsor shows involvement in minimal residual disease assessment, ctDNA-based monitoring, and organoid-guided treatment selection.
- ctDNA clearance
- Minimal residual disease
- Organoid-based treatment guidance
These interests connect biomarker-driven evaluation with therapy choice in haematology and solid tumours.
